Printer Friendly

Molecular devices purchases Transfluor imaging technology.

Sunnyvale, CA 3/9/05 -- Molecular Devices has acquired Xsira Pharmaceuticals' Transfluor technology assets for $11 million in cash. Transfluor technology comprises cell-based fluorescent assays for imaging and G-protein coupled receptor (GPCR) studies that are used with imaging platforms, such as Molecular Devices' Discovery-1 and ImageXpress systems. Molecular Devices will begin licensing the technology to its customers in the second quarter. "With a product portfolio that includes Transfluor technology, our Fluorometric Imaging Plate Reader (FLIPR), and reagents, Molecular Devices now offers best-in-class screening solutions for every major type of GPCR target," said Dr. Michael Sjaastad, director of Marketing for Molecular Devices Imaging.

Notably, this purchase expands Molecular Devices' consumables business and also gives it a new way to reach potential instrument customers. The acquisition includes intellectual property (IP) rights, certain third-party contracts pertaining to the IP, contracts granted for the technology as well as related biological materials and documents. Xsira was also granted a royalty-free, fully paid license.
COPYRIGHT 2005 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Executive briefing: news, trends & market intelligence for instrument executives
Publication:Instrument Business Outlook
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 15, 2005
Previous Article:Smiths adds to security technology portfolio.
Next Article:MWG biotech sells microarray assets.

Related Articles
AMETEK acquires Chandler Instruments.
Molecular Devices and Caliper reach settlement.
Waters acquires NuGenesis Technologies.
2004 acquisitions keep instrument companies busy.
Instrumentation and cell-based assays.
Industry productivity falls as employment rises.
Molecular devices lowers third quarter guidance.
2007 mergers & acquisitions review.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters